Strong Third Quarter Results
Third quarter revenue totaled $223 million, a nearly 8% increase from last year's third quarter. Adjusted EBITDA was $52.4 million, up 14.7% versus third quarter last year.
Nuclear Power End Market Growth
Nuclear power end market organic revenue grew 9% in the quarter and 11% year-to-date. Adjusted orders increased 21% in the quarter.
Cost of Debt Improvement
Year-end 2025 expected blended cost of debt of 2.8%, reflecting a 460 basis point improvement over the past year.
Positive Free Cash Flow
Third quarter adjusted free cash flow was $18 million, contributing to $53 million of year-to-date adjusted free cash flow. Adjusted free cash flow guidance increased to between $100 million and $115 million.
Medical Segment Progress
Third quarter organic revenue from dosimetry services grew 7% with digital offerings leading. Medical segment margins expanded 120 basis points to 35.9%.